NCT06352359

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Name: Clinical Trial NCT06352359
Creator: OncoC4, Inc.
Keywords: Advanced Solid Tumor, ONC-841, Phase 1, drug, clinical trial, United States of America

OncoC4, Inc.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Advanced Solid Tumor
Drug/Device/Intervention: ONC-841
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: OncoC4, Inc.
Location: Sacramento,Louisville,Houston, United States of America

Timeline & enrollment

Phase: Phase 1
Start date: Jun 30, 2024
End date: Jun 30, 2027
Enrollment: 30 participants

Primary outcome

Dose Limiting Toxicity (DLT),Maximum Toxicity Dose (MTD)

Summary

This is a Phase I open label, dose-escalation study of intravenous (IV) infusion of ONC-841 as a single agent in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841 starting from 0.03 mg/kg to 30 mg/kg.

ICD-10 classifications

Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06352359
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06352359 through Pure Global AI's free database. This Phase 1 trial is sponsored by OncoC4, Inc. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.